Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.

By J. Naidoo, Xuan Wang, K. Woo, T. Iyriboz, D. Halpenny, J. Cunningham, J. Chaft, N. Segal, M. Callahan, A. Lesokhin and 19 more. Journal of Clinical Oncology, 2017

1,030 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/c9427a857b5f3e3bdb823efcd666af52d64a5e15

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. J. Wolchok
2. C. Robert
3. K. Kerr
4. J. Haanen
5. J. Larkin
6. S. Peters
7. F. Carbonnel
8. M. Lacouture

Citations in the corpus

• Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline (2018, background): “pneumonitis was reported to develop in both former/current smokers (56%) and never smokers (44%).(38) Recent evidence also demonstrated no significant difference in the rates of irAEs, including pneumonitis, between patients who received thoracic radiotherapy in addition to checkpoint inhibitors.”
• Myocarditis in Patients Treated With Immune Checkpoint Inhibitors (2018, neutral): “This contrasts with the low incidence of severe pneumonitis with anti-PD1 or anti-PDL1 (4% grade 4 or 5) (25), severe”
• Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018, background): “Incidence of pneumonitis was recently reported in a multicentre large retrospective analysis of patients receiving anti-PD1/PD-L1 monotherapy or in combination with anti-CTLA4, as diagnosed by the treating investigator after exclusion of a tumoural or infectious aetiology [67].”
• Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2017, background): “Tapering of steroids should be very slow and careful, over 6 weeks or more; relapses of pneumonitis during steroid tapering have been reported, adding considerations about recurrence in patients who rechallenge immunotherapy [66].”
• Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update (2021, background): “In a multicenter, large, retrospective analysis, pneumonitis was reported in both former or current smokers (56%) and never smokers (44%).(103) Recent evidence also demonstrated no significant difference in the rates of irAEs, including pneumonitis, in patients who received thoracic radiotherapy and”
• Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group (2017, background): “Combination therapies with anti-CTLA-4/anti-PD-1/PD-L1 immunotherapy and with ICI/cytotoxic combinations also confer a higher risk of pneumonitis versus ICI monotherapy [68, 70].”